Literature DB >> 15590794

Midterm results after atherectomy-assisted angioplasty of below-knee arteries with use of the Silverhawk device.

Thomas Zeller1, Aljoscha Rastan, Uwe Schwarzwälder, Ulrich Frank, Karlheinz Bürgelin, Pietro Amantea, Christian Müller, Hans Krankenberg, Peter-Christian Flügel, Franz-Josef Neumann.   

Abstract

PURPOSE: Prospective evaluation of the 3- and 6-month results after atherectomy of below-knee arterial lesions with a reference diameter of at least 2.0 mm with use of the Silverhawk device.
MATERIALS AND METHODS: Fifty-two below-knee lesions in 33 patients (61% men; mean age, 70 years +/- 11) with chronic peripheral occlusive disease of the lower limbs were treated with directional atherectomy. Target lesions were the popliteal artery (segment 3), n = 4 (8%); tibioperoneal trunk, n = 22 (42%); peroneal artery, n = 18 (34%); anterior tibial artery, n = 5 (10%); posterior tibial artery, n = 3 (6%); and in-stent lesions, n = 8 (16%). All interventions were performed via a 6-F sheath. The average degree of diameter stenosis was 89% +/- 10% (range, 70%-100%; n = 12 [23%] occlusions) and the mean lesion length was 48 mm +/- 28.
RESULTS: All but one lesion (2%) could be treated with the atherectomy catheter. After additional balloon angioplasty, all but one lesion was treated, with a residual stenosis no greater than 30% (98%), with 7.2 passes per lesion +/- 2.8 (range, 1-12) performed with the device. Fifteen lesions (29%) were treated after predilation and 37 (71%) were treated with primary atherectomy. In 15 lesions (29%), additional balloon angioplasty was performed, and two lesions required stent implantation as a result of dissection. The mean stenosis diameter after atherectomy was 12% +/- 18% (range, 0-100%). After additional therapy, the mean stenosis diameter was 6% +/- 9% (range, 0%-30%). A residual stenosis no greater than 30% was achieved in 50 lesions (96%). The mean ankle-brachial index significantly increased from 0.46 +/- 0.27 to 0.80 +/- 0.34 before discharge and remained improved during follow-up. One procedural complication (3%) was observed in which an intermittent occlusion of the target vessel occurred after an unsuccessful attempt to cross the lesion with the atherectomy device; this was then treated successfully with local lysis. One patient with one treated lesion died during follow-up. The rates of restenosis of at least 70% (diagnosed by duplex ultrasonography) were 14% (seven of 51 lesions) after 3 months and 22% (11 of 51) after 6 months. The 3-month and 6-month cumulative event-free survival were 91% +/- 4.1% and 76.9% +/- 5.8% and the 3-month and 6-month cumulative patency rates were 98% +/- 1.9% and 94.1% +/- 3.3%, respectively.
CONCLUSION: Below-knee native vessel lesions with a diameter of at least 2.0 mm can be treated with the Silverhawk catheter with a high success rate and a low complication rate. Midterm technical and clinical results are encouraging. Additional balloon angioplasty might be necessary in selected cases.

Entities:  

Mesh:

Year:  2004        PMID: 15590794     DOI: 10.1097/01.RVI.0000138060.05915.9D

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  13 in total

1.  An Update on Methods for Revascularization and Expansion of the TASC Lesion Classification to Include Below-the-Knee Arteries: A Supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II): The TASC Steering Comittee(.).

Authors:  Michael R Jaff; Christopher J White; William R Hiatt; Gerry R Fowkes; John Dormandy; Mahmood Razavi; Jim Reekers; Lars Norgren
Journal:  Ann Vasc Dis       Date:  2015-10-23

2.  Endovascular revascularization of symptomatic infrapopliteal arteriosclerotic occlusive disease: comparison of atherectomy and angioplasty.

Authors:  Tze-Woei Tan; Elie Semaan; Wael Nasr; Robert T Eberhardt; Naomi Hamburg; Gheorghe Doros; Denis Rybin; Palma M Shaw; Alik Farber
Journal:  Int J Angiol       Date:  2011-03

3.  Combined HawkOne directional atherectomy and paclitaxel-coated balloon angioplasty for isolated calcified popliteal artery lesion: a no-stent approach to lower extremity endovascular revascularization.

Authors:  Romaric Loffroy; Olivier Chevallier; Nicolas Falvo; Sophie Gehin; Marco Midulla; Christophe Galland
Journal:  Quant Imaging Med Surg       Date:  2018-04

4.  Endovascular treatment of femoropopliteal stenoses/occlusions with a SilverHawk directional atherectomy device: immediate results and 12-month follow-up.

Authors:  R Regine; O Catalano; M De Siero; G Di Costanzo; A Ragozzino
Journal:  Radiol Med       Date:  2010-07-31       Impact factor: 3.469

5.  Tibial intervention for critical limb ischemia.

Authors:  Bret N Wiechmann
Journal:  Semin Intervent Radiol       Date:  2009-12       Impact factor: 1.513

6.  Plaque Excision in Management of Lower Extremity Peripheral Arterial Disease with the SilverHawk Atherectomy Catheter.

Authors:  Martin G Radvany; R Stefan Kiesz
Journal:  Semin Intervent Radiol       Date:  2008-03       Impact factor: 1.513

Review 7.  [Percutaneous mechanical atherectomy for treatment of peripheral arterial occlusive disease].

Authors:  A Buecker; P Minko; A Massmann; M Katoh
Journal:  Radiologe       Date:  2010-01       Impact factor: 0.635

8.  Use of embolic protective devices in treating acute arterial occlusions: an interventional radiology and vascular surgery collaborative learning experience.

Authors:  Joel Woodley-Cook; Vikram Prabhudesai; Tony Moloney
Journal:  BMJ Case Rep       Date:  2013-04-10

9.  Endovascular management of the popliteal artery: comparison of atherectomy and angioplasty.

Authors:  Elie Semaan; Naomi Hamburg; Wael Nasr; Palma Shaw; Robert Eberhardt; Jonathan Woodson; Gheorghe Doros; Denis Rybin; Alik Farber
Journal:  Vasc Endovascular Surg       Date:  2009-11-25       Impact factor: 1.089

10.  Chronic Femoropopliteal Occlusions: Comparison of Drug-Eluting Balloon Angioplasty with or without Prior Rotational Thrombectomy.

Authors:  Burak Teymen; Süleyman Aktürk
Journal:  Acta Cardiol Sin       Date:  2020-03       Impact factor: 2.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.